In 2020, Luke Turnock — a senior lecturer in criminology at the University of Lincoln who studies how people use enhancement drugs — was at a gym when he encountered a man injecting himself with BPC-157 to treat tennis elbow. The man's source was Amazon. "That's when I realised, this is suddenly way more mainstream," Turnock later said.
Six years on, that mainstreaming has accelerated dramatically. Imports of peptide compounds from China reached an estimated $328 million in the first three quarters of 2025, roughly double the same period in 2024. Subreddits dedicated to peptide use have hundreds of thousands of members. "Peptide raves" — events where participants receive instruction on reconstituting and injecting compounds — have been reported in major cities. And in February 2026, the US Secretary of Health and Human Services publicly backed the practice on one of the world's most listened-to podcasts.
So who, exactly, is doing this — and what do we actually know about how it's going for them?
The community is not who most people assume
The popular image of the peptide self-experimenter is a gym-obsessed bodybuilder or a Silicon Valley executive with too much money and too little patience for conventional medicine. Both exist in the community. Neither is representative of it.
Turnock, who published research on the "folk pharmacology" of peptide users in online forums, describes the population as significantly more diverse than the stereotype suggests. The forums he studied skewed heavily toward people in their 30s and 40s, with meaningful representation from medically literate professionals — nurses, pharmacists, physicians — who were applying clinical reasoning to their self-experimentation even if their conclusions weren't always what mainstream medicine would endorse.
The reasons people give for using research peptides cluster into a few distinct motivations, and they're worth taking seriously on their own terms before evaluating the evidence behind them.
The chronic injury cohort
The single most common driver in community discussions is injuries that conventional medicine hasn't resolved. Torn tendons, persistent ligament damage, chronic joint inflammation, spinal disc issues — conditions where the standard of care is either surgery with a long uncertain recovery, or indefinite pain management that addresses symptoms without addressing tissue damage. BPC-157 and TB-500, with their preclinical data on angiogenesis and tissue repair, are the compounds most frequently used in this context.
The community discussions around these users are notably methodical. People post detailed logs of their protocols, dosing, timing, and outcomes over weeks and months. They debate the relative merits of local versus systemic injection. They reference the underlying research, critique its limitations, and share observations about what they're noticing in their own bodies. It reads less like recreational drug culture and more like a patient-led clinical community filling a gap that formal medicine hasn't addressed.
The longevity cohort
A distinct and growing segment is using peptides not to treat acute conditions but as preventive longevity interventions. GHK-Cu, Epithalon, MOTS-c, NAD+ precursors, and mitochondrial peptides like SS-31 appear most frequently here. These users tend to be older — often 40s and 50s — and are frequently running comprehensive biomarker testing alongside their protocols. They're tracking blood panels, metabolic markers, and in some cases wearable biometrics, attempting to build an evidence base for their own interventions that the formal research system hasn't provided.
Bryan Johnson's public "Blueprint" protocol — one of the most documented self-experimentation projects in history — has influenced this cohort significantly, normalising the idea of treating one's own body as a system to be optimised with measurable inputs and outputs.
The performance cohort
Athletes — including competitive athletes in tested sports — represent a smaller but significant portion of the community. Growth hormone secretagogues (ipamorelin, CJC-1295, MK-677) are the primary compounds here, used for body composition, recovery, and sleep quality. This cohort carries the highest regulatory risk: BPC-157 has been on WADA's prohibited list since 2022, and metabolites remain detectable in urine for four to five days after administration.
The Silicon Valley angle, while real, is frequently overstated in mainstream coverage. A supplier of Chinese peptides quoted by the New York Times observed that their average customer is "closer to a Starbucks barista" than a tech executive — a comment that captures something true about how far the practice has spread beyond its early adopter base.
The numbers behind the phenomenon
What conventional medicine gets wrong about these users
The standard public health response to self-experimentation with research peptides is a version of: these compounds are unproven, the risks are unknown, don't do it. This position is scientifically defensible. It's also largely failing to engage with the people it's intended to reach.
Stuart Phillips, a professor at McMaster University who has studied the evidence base for research peptides, puts the scientific case plainly: the preclinical data is interesting enough to warrant proper human investigation, but it doesn't justify self-experimentation. Roughly 90% of drugs that show promise in animals fail in human trials. The few human studies on BPC-157 involve fewer than 30 subjects combined, with no control groups and no randomised placebo-controlled designs.
This is a legitimate scientific critique. But it misses something important about why the community exists and why warnings don't resonate.
The people in these forums are, by and large, aware that the human evidence is thin. They've read the same systematic reviews. They're not operating under the illusion that BPC-157 has been proven in controlled trials. What they've concluded — rightly or wrongly — is that the risk-benefit calculation for their specific situation justifies trying a compound with compelling preclinical data and a low reported adverse event rate, when the alternative is continuing to live with an injury that conventional medicine has not resolved.
"They're trying to sell this idea of, you take this, and you will be better than well."
Luke Turnock, University of Lincoln criminologist studying enhancement drug communitiesThat framing is more nuanced than "ignoring the science." It's a reasonable — if genuinely risky — application of personal risk tolerance to a situation where formal medical options have been exhausted or are inaccessible. It also reflects a broader erosion of institutional trust that the peptide phenomenon sits within but did not create.
The regulatory paradox that made this worse
The FDA's 2023 decision to place 19 widely used peptides on its Category 2 restricted list — cutting off licensed compounding pharmacies from producing them — was intended to reduce access to compounds with insufficient safety data. The actual effect was the opposite.
Before the restriction, a meaningful portion of peptide use occurred through licensed compounding pharmacies under physician supervision. Patients had prescriptions. Pharmacies operated under USP 797 and 795 compliance standards. Products had verified sterility, potency, and purity. It wasn't a perfect system, but it was a supervised one with quality controls.
The 2023 restriction eliminated that pathway. It did not eliminate demand. What it did was redirect that demand entirely into the grey market — Chinese synthesis facilities, research chemical vendors, online suppliers operating under "for research use only" disclaimers. HHS Secretary Kennedy acknowledged this directly in his February 2026 announcement, describing the Category 2 designations as having "pushed demand toward an unregulated black market rather than reducing access."
The result: more people using these compounds than before, with less quality assurance than before. The 30% mislabelling and contamination rate found in Finnrick's testing of market products captures this outcome clearly. The people most harmed by the regulatory overcorrection are the ones the regulation was ostensibly designed to protect.
What the community data actually shows — and what it doesn't
Adverse event reporting in communities like r/Peptides is, relative to estimated use volume, strikingly low. This is worth examining honestly rather than dismissing.
The obvious interpretation is that these compounds are reasonably safe in the doses and protocols being used. The less obvious — and equally valid — interpretation is that online forums systematically underreport negative outcomes. People who have bad experiences tend to disengage from communities rather than post detailed adverse event reports. The absence of visible negative reports is not the same as evidence of safety.
What the community data does show with more reliability is patterns of use, preferred protocols, and the kinds of effects people report noticing — positive and neutral. The most consistent positive reports across multiple compounds are for injury recovery (BPC-157, TB-500), skin quality (GHK-Cu), sleep improvement (MK-677, Epithalon, DSIP), and body composition (GH secretagogue stacks). These are subjective reports, not controlled observations, and placebo effects in this context could be substantial.
The most consistent risk reports are not compound-related adverse events but sourcing-related problems: products that don't reconstitute correctly, protocols that produce no effect (suggesting underdosed or counterfeit products), and injection site reactions that likely reflect contamination or incorrect technique rather than the peptides themselves.
The clearest and best-documented risk in the self-experimentation community is not the compounds themselves — it's sourcing quality. 30% of tested products contain incorrect dosages, are mislabelled, or are contaminated. This means a significant portion of people who believe they're taking a specific peptide at a specific dose are doing something quite different. The harm reduction implication is clear: COA verification from independent laboratories is not optional, it's the minimum viable safety measure. A product without a current, batch-matched third-party COA is a product you cannot characterise.
The compounds that dominate
Community use isn't evenly distributed across peptides. A handful of compounds account for the vast majority of activity, and the reasons for their prominence are instructive.
BPC-157 remains the most widely used research peptide by a significant margin. Its research portfolio — despite being almost entirely preclinical — is the most extensive of any compound in this space, and its reported adverse event profile across millions of user-administrations is strikingly clean. The regulatory battle over it has, paradoxically, increased its profile.
GHK-Cu is the fastest growing compound, having made the transition from research community to mainstream skincare culture. Its +1,016% year-on-year search growth reflects a new and much larger audience — predominantly women interested in skin aging — who are using topical forms rather than injectable. This is a categorically lower-risk route of administration that sits in a very different part of the risk spectrum from the injectable community.
Semaglutide and tirzepatide occupy a separate category — grey-market versions of FDA-approved drugs rather than research compounds. The motivations here are primarily economic: branded GLP-1 drugs cost over $1,000 per month; grey-market equivalents reportedly cost roughly a fifth of that. The risks are different in kind — product quality rather than compound safety — but the scale of use dwarfs everything else in the peptide space.
Growth hormone secretagogue stacks — ipamorelin combined with CJC-1295 being the most common — are the dominant protocol in the performance and body composition cohort. These are generally lower-risk than direct GH administration, operating through the body's own regulatory feedback mechanisms rather than introducing exogenous hormone directly.
What's about to change
The July 2026 FDA Pharmacy Compounding Advisory Committee meeting represents the most significant regulatory moment for this community since the 2023 restrictions. BPC-157, KPV, Semax, GHK-Cu, MOTS-c, and several other commonly used compounds will be evaluated by independent scientific advisers. A positive recommendation for any compound would restore the legal compounding pathway — physician prescription, licensed pharmacy, verified quality.
That pathway matters not because it would significantly change who uses these compounds, but because it would change the quality of what they're using. The supervised compounding framework provides something the grey market structurally cannot: sterility testing, potency verification, and pharmaceutical-grade manufacturing standards. For a community where sourcing contamination is the primary documented harm, that distinction is not academic.
Whether the PCAC recommendations will translate into formal reclassification — and on what timeline — remains to be seen. What's clear is that the community of people making these decisions for themselves will continue to grow regardless of what regulators decide. The more interesting question is whether the regulatory environment will evolve to reduce the risk of that self-experimentation, or continue to create conditions that make it more dangerous.